Savara

+$0.04 (+3.13%) Today
-$0.04 (-3.03%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The firm's lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis.

CEO
Matthew Pauls
Employees
22
Headquarters
Austin, Texas
Founded
1995

SVRA Key Statistics

Market cap
150.53M
Price-Earnings ratio
—
Dividend yield
—
Average volume
130.20K
High today
$1.34
Low today
$1.27
Open price
$1.28
Volume
55.05K
52 Week high
$1.91
52 Week low
$1.02

SVRA Earnings

-$0.23
-$0.15
-$0.08
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 11, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure